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Background and aims: Many patients presenting multiple behaviors including drug and food abuse as well as other
pathological repetitive unwanted activities such as gambling, self-mutilation and paraphilias may not be appropri-
ately diagnosed. Here we present a case of a male presenting many of these seemingly diverse behaviors and finally
diagnosed with reward deficiency syndrome (RDS) by his attending physician. Methods: The use of the dopamine
agonist, ropinirole after two weeks showed improvement in terms of sexual behavior but tolerance set in and was dis-
continued especially when an infraction occurred with the patient’s insurance. In this article, we carefully explore the
potential of ropinirole to downregulate dopamine receptors causing adenylate cyclase receptor supersensitivity and
tolerance a feature of neurotransmitter cross-talk. Based on previous scientific evidence showing KB220Z-
nutrigenomic amino-acid therapy (NAAT) to rapidly (post one-hour) activate dopaminergic pathways in both the
pre-frontal cortex cingulate gyrus (relapse loci) and ventral tegmental area–caudate–accumbens–putamen (craving
and emotion loci) the patient was prescribed NAAT. Results and discussion: Within one week of utilization the re-
petitive paraphilia was eliminated. There were also a number of other positive effects such as enhanced focus that
persisted even after the patient stopped using KB220Z suggesting neuroplasticity (e.g. altruistic thoughts). However,
these observed profound benefits require more in-depth study, especially in a large cohort against a placebo. While
this report focused on a rapid response rather than long-term benefits previously associated with NAAT, it is some-
what encouraging and longer term required follow-up and larger placebo controlled studies are warranted before any
definitive conclusions could be gleaned from this case report.
Keywords: aggressive sexual behavior, repetitive paraphilia behavior, Tourette’s, dopamine activation, NAAT, re-
ward deficiency syndrome (RDS)
BACKGROUND
It is difficult to define deviant sexual behavior. For thou-
sands of years cultures define and describe what is normal
and what is deviant. According to Bhugra, Popelyuk and
McMullen (2010), these definitions of normality vary across
cultures and are influenced by a number of factors, such as
religion and other familiar factors. Most importantly, the
role and development of paraphilias across cultures is vari-
able, with cultures mandating what is legal or illegal.
Paraphilia (from Greek para [parÀ] = beside and -philia
[íil«a] = friendship, meaning love) describes sexual arousal
to objects, people, or situations, that are not part of norma-
tive stimulation. According to DSM-IV, paraphilia includes
sexual arousal and gratification, involving a sexual behavior
that is atypical or extreme (American Psychiatric Associa-
tion, 2000–2006). Historically, the term was coined by
Stekel in the 1920s (1930). Furthermore, Money (1990) a
sexologist, popularized the term as a nonpejorative designa-
tion for deviant or unusual sexual interests (“a sexuoerotic
embellishment”). It is noteworthy, that before the introduc-
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tion of the term paraphilia in the DSM-III (1980), the term
sexual deviation was used to refer to paraphilias in the first
two editions of the manual (Spitzer, 1981). Indeed
paraphilia has been described (Moser & Kleinplatz, 2005) as
“recurrent, intense sexually arousing fantasies, sexual urges,
or behaviors generally involving”:
1. Non-human objects.
2. The suffering or humiliation of oneself or one’s part-
ner.
3. Children.
4. Non-consenting persons.
Finally, the DSM-5 Paraphilias Workgroup reached a
“consensus that paraphilias are not ipso facto psychiatric
disorders”, and suggested “that the DSM-5 make a distinc-
tion between paraphilias and paraphilic disorders”. Thus, a
paraphilia by itself would not automatically justify or re-
quire psychiatric intervention. As such a paraphilic disorder
is a paraphilia that causes distress or impairment to the indi-
vidual or harm to others like other addictions as proposed in
reward deficiency syndrome, RDS) (Blum et al., 1996). The
workgroup further proposed that one would ascertain a
paraphilia (according to the nature of the urges, fantasies, or
behaviors) but diagnose a paraphilic disorder (on the basis
of distress and impairment). In this new conception, “having
a paraphilia would be a necessary but not a sufficient condi-
tion for having a paraphilic disorder”.
Recently, our laboratory reviewed the commonality of
drugs, food, music, and other behavioral addictions includ-
ing sex referring to the concept of “sex, drugs and rock ’n’
roll” (Blum, Werner et al., 2012). In essence, the nucleus
accumbens (NAc), a site within the ventral striatum, plays a
prominent role in mediating the reinforcing effects of drugs
of abuse, food, sex, and other addictions. It is generally be-
lieved that this structure mandates motivated behaviors such
as eating, drinking, and sexual activity, which are elicited by
natural rewards and other strong incentive stimuli. We hy-
pothesized, a common underlying mechanism of action for
the powerful effects that all addictions have on human moti-
vation. Moreover, biological drives may have common mo-
lecular genetic antecedents, which if impaired, lead to patho-
logical behaviors. We pointed out that based on scientific
support, dopaminergic genes, and possibly other candidate
neurotransmitter-related gene polymorphisms, affect both
hedonic and anhedonic behavioral outcomes.
We firmly believe genotyping studies already have
linked gene polymorphic associations with alcohol and drug
addictions and obesity (Gardner, 2011), and we anticipate
that future genotyping studies of sex addicts will provide ev-
idence for polymorphic associations with specific clustering
of sexual typologies based on clinical instrument assess-
ments (Daw & Guo, 2011; Guo & Tong, 2006; Miller et al.,
1999).
While there is a paucity of genetic research on paraphilia
behavior per se, there are studies relating polymorphisms of
dopaminergic genes (e.g. DRD2 and DRD4 genes) and sex-
ual behavior especially related to onset of sexual intercourse
(Miller et al., 1999; Guo & Tong, 2006) and unprotected sex
(Daw & Guo, 2011). Specifically, Daw and Guo (2011)
found in the Longitudinal Study of Adolescent Health that
variants in the dopamine transporter gene DAT1, the dopa-
mine receptor gene DRD2, and the monoamine oxidase gene
MAOA are associated with unprotected sexual intercourse.
Interestingly, the genotypes DRD2*A1/A2, DRD2*A2/A2,
DAT1*9R/10R, and MAOA*2R/ are associated with higher
odds of unprotected sexual intercourse than other genotypes
at these loci. Their data also revealed that the DRD2 associa-
tions apply to both men and women, whereas the other asso-
ciations apply to women only.
It is our opinion that both scientists and clinicians em-
bark on research coupling the use of neuroimaging tools
with dopaminergic agonistic agents to target specific gene
polymorphisms systematically for normalizing hyper- or
hyposexual behaviors.
Brief description of KB220Z
KB220Z is a neuroadaptogen consisting of amino-acid neu-
rotransmitter precursors and catechol-O-methyltransferase
(COMT)/monamine-oxidase (MOA) inhibition therapy
called “neuroadaptogen amino-acid therapy™” (NAAT)
that works in synchrony with brain reward function (see
Table 1). It is becoming increasingly clear that this novel
formulation is the first neuroadaptogen known to activate
the brain reward circuitry (Chen et al., 2011). Ongoing re-
search repeatedly confirms numerous clinical effects that ul-
timately result in significant benefits for victims having ge-
netic antecedents for all addictive, compulsive and impul-
sive behaviors. As mentioned earlier, these behaviors are
correctly classified under the rubric of “reward deficiency
syndrome” (Blum et al., 1996), involving hypodopami-
nergic function in the meso-limbic system of the brain. Acti-
vation of brain reward circuitry using NAAT (KB220Z) has
been demonstrated in the United States using qEGG (Blum,
Stice et al., 2011) and in preliminary findings in China using
fMRI in victims of “substance use disorder” (SUD). In un-
published data using an fMRI 2X2 design at resting state
(Chen et al., 2011) NAAT in comparison to placebo showed
activation of the caudate brain region and potentially a
smoothing out of heroin-induced abnormal connectivity in
the putamen (a site for emotionality). Although awaiting fi-
nal analysis, if confirmed by ongoing studies in China cou-
pled with published qEEG results in America, showing an
increase in alpha and low beta, as well as fMRI studies ongo-
ing in the United Sates, NAAT may be shown to impact
treatment outcomes and relapse.
OBJECTIVES
Based on these and 25 earlier clinical trials (Chen et al.,
2011) we decided to test the potential of using
KB220Z-NAAT as a safe natural modality to attenuate re-
fractive paraphilia behavior of a medication refractive
Table 1. KB220Z-nutrigenomic amino-acid therapy (NAAT)
GRAS nutrient pathway
D-phenylalanine Opioid peptides
L-phenylalanine Dopamine
L-tryptophane Serotonin
L-tyrosine Dopamine
L-glutamine GABA
Chromium Serotonin
Rhodiola rosea COMT/MOA
Pyridoxine Enzyme catalyst
Tourette’s syndrome patient. We hypothesized that since
this complex has been shown to activate dopaminergic path-
ways and enhance decision-making as a result of PFC-
cingulate gyrus regulation, that it may reduce paraphilias
rapidly.
It is not uncommon for patients with Tourette’s to dis-
play obsessive–compulsive tendencies including sexual ob-
sessions (James, 1995; Mack et al., 2010). Furthermore,
Comings (1994) reported that individuals with Tourette’s
show deviant sexual behaviors (paraphilias) in some cases
including magnitude of sex drive, sex orientation, exhibi-
tionism, transvestitism, transsexualism, sadism, masochism,
pedophilia, fetishism, aversion to being touched, and aver-
sion to sex. Accordingly (Comings, 1994), there was a sig-
nificant positive correlation between each behavior exam-
ined and the degree of genetic loading for the Tourette’s
gene(s). In fact unlike our patient there is evidence for recur-
rent paraphilic masturbatory fantasy (Kerbeshian & Burd,
1991). In terms of potential neurochemical correlates of
paraphilic behavior in Tourette’s it has been shown that the
opiate receptor blocker naltrexone ameliorated paraphilic
behaviors in patients refractive to conventional anti-
Tourette’s drugs including haloperidol and clonidine
(Sandyk, 1988). There is evidence for the role of dopa-
minergic signaling and behavior, attractiveness to opposite
or same gender and bonding in animal models (Banerjee,
1974; Chen, Liu, Ren & Guo, 2012; Wang & Aragona,
2004).
Essential features and uniqueness of the case
The patient is a 35-year-old male, living with his ex-girl-
friend. During his initial evaluation, 6 years ago, he stated
that “I have bipolar, mood disorder”. Prior to this, he had
been treated with venlafaxine and sertraline, without a clini-
cal effect. He reported a tendency to spend all his money at
once and had $46,000 in credit card debt. The onset of his
depressed mood followed the death of his father, when the
patient was 16 years old. He developed a lack of motivation
as well as insomnia and stated that these symptoms became
worse each year. He also reported social anxiety and panic
attacks.
Social history
Patient is a high school graduate with a history of learning
disabilities. He worked as a carpenter and cabinet maker. He
tended to miss work, intermittently, and was placed on So-
cial Security Disability. He never married and had no chil-
dren. He was living with his ex-girlfriend and described
their relationship as “just friends”. He denied any court in-
volvement.
Substance abuse history
Patient denied current use of alcohol but reported a prior his-
tory of alcoholism for four years, when he drank to the point
of intoxication on weekends. He denied current use of illicit
drugs, but reported a history of using ecstasy about 30–40
times. He admitted to using LSD twice, with one bad trip. He
had been using marijuana regularly for the previous six
months. He reported a history of prescription, drug abuse
but denied any use of cocaine, angel dust, crystal meth, or
heroin.
Past psychiatric history
His first psychiatric treatment occurred three years prior,
when he was hospitalized because of suicidal ideation. He
saw a psychiatrist 2 years prior to this, following a brief at-
tempt at psychotherapy.
Past medical history
Patient denied any history of asthma, hypertension, coronary
artery disease, seizures, or serious head injury. He took medi-
cation for hypothyroidism. There were no known allergies.
Family psychiatric history
Father was an alcoholic and a substance abuser. Patient’s
mother suffered from social anxiety disorder and had also
abused drugs and alcohol.
Family history
Patient’s mother was 57 years old and is described as “quiet,
private, and unable to show her feelings”. She had a history
of alcoholism and never engaged in any playful activities
with the patient nor was she affectionate. His father died at
the age of 45 from cancer. He had a history of alcoholism
and the patient described him as “cold, distant, cruel and sa-
distic”. He did not engage in any activities with the patient
when he was a child and was not affectionate. His father was
physically abusive and would smack the patient. He was ver-
bally abusive and would call his son, a “faggot”. He reported
his father would tease him and say that he “looked like a
fairy”. His father would hit 2 to 3 times a week and, at age
11, his father threw him across a room. When asked whether
he had suffered sexual abuse as a child, he stated “I wonder”.
He has two siblings, a brother and sister, with whom he has
normal relationships.
Mental status examination
Patient was alert and oriented in all three spheres. He was
pleasant and cooperative. His mood was moderately de-
pressed. He denied suicidal or homicidal ideation, but ad-
mitted to passive wishes to die. He denied auditory halluci-
nations, but reported visual hallucinations, involving ani-
mals. He also reported ideas of reference but denied delu-
sions, obsessive–compulsive symptoms, or panic symp-
toms. He denied periods of full-blown mania. He admitted to
social anxiety and reported decreased sleep (five hours),
with recently increased appetite.
Diagnoses
Axis I: major depressive disorder, social anxiety disor-
der and rule out bipolar disorder.
Axis II: deferred.
Axis III: hypothyroidism.
Axis IV: moderate-symptom management.
Axis V: CGAF 45.
Review of psychopharmacology progress notes
Initially, the patient weighed 230 pounds (104.326 kg) and
was 5 feet 10 inches tall (177.8 cm). He reported a strong
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need for pornography. His father was also addicted to por-
nography. The patient had experienced a 50% decrease in
his interest in pornography, when his primary care physician
had increased from his venlafaxine from 75 mg to 150 mg.
He later reported his interest in pornography had decreased
by 80%, out of consideration for his live-in girlfriend. One
month into treatment, he reported he had had no sexual rela-
tions for two weeks and that his interest in pornography had
decreased to one episode within the past week. Two months
into treatment, he viewed pornography about once a week.
Three months into treatment, he viewed pornography one to
two times a week. He reported that he was overly preoccu-
pied with computers. Six months into treatment, he was pre-
scribed dextropropoxyphene, following a tooth infection.
He became suicidal, when he ran out of dextropropoxy-
phene. At this time, his interest in pornography had in-
creased. He stated that his interest in sex would fluctuate.
Ten months into treatment, he watched pornography daily
and his sexual relations with his girlfriend had been on hold,
because of her medical issues. Eleven months into treatment,
he admitted to occasional pornography viewing on the
Internet. There seemed to be no relationship with the fre-
quency of his relations with his girlfriend. Eighteen months
into treatment, because of a new diagnosis of Tourette’s syn-
drome and, because of one of the authors’ (TM) familiarity
with the rubric, “reward deficiency syndrome”, the dopa-
mine agonist, ropinirole, was started at the recommended ti-
tration rate. Two weeks later, AC reported an improvement
in his hygiene (teeth brushing) and more motivation to orga-
nize things around the home. Ropinirole was increased to 1
mg at HS. After 2 weeks, he stated that he felt sexually
“more tender” towards his girlfriend. Twenty months into
therapy, he complained of no libido. Twenty-two months
into treatment his ropinirole was increased to 1.5 mg and,
then 2 mg. Initially, he felt his sexuality was more sensual
but then he complained about feeling “more hyper” and his
ropinirole was tapered to 1 mg. Twenty-three months into
treatment, he continued to feel sexually more tender towards
his girlfriend. Twenty-four months into treatment, he com-
plained of racing thoughts and decreased sleep. Ropinirole
was discontinued and quetiapine was started at 100–400 mg
at HS. Dextroamphetamine/amphetamine was added, be-
cause of the patient’s complaint of long-standing difficulties
in concentrating. He was also diagnosed with ADHD.
Twenty-five months into treatment, ropinirole titration was
re-instituted. Paroxetine was prescribed for social anxiety
disorder. Twenty-six months into treatment, the patient re-
ported a history of vocal tics, involving throat clearing. He
also described finger twitching, finger waggling, a compul-
sive need to touch everything as well as an impulsive ten-
dency to blurt out sexually inappropriate comments and en-
gage in sexually inappropriate behaviors. Twenty-six
months into treatment, paroxetine was added to his regimen,
because of increased sexual urges. Ropinirole was again in-
creased to 1.5 mg at HS. Along treatment hiatus ensued.
Twenty-eight months into treatment, he reported a long-
standing hypersensitivity to certain smells. Ropinirole had
to be re-titrated, because of non-compliance as well as insur-
ance problems. Twenty-nine months into treatment, the pa-
tient’s concentration was “almost perfect”. He had de-
creased hyperfocusing, e.g. videogame watching. Thirty
months into treatment, the patient reported continued, de-
creased interest in video games. He was increasingly affec-
tionate (vs. sexually aggressive) towards his girlfriend.
Thirty-one months into treatment, the patient reported in-
creased motivation and excellent concentration. He again
stopped both his dextroamphetamine/amphetamine (be-
cause he was feeling “hyper”) and his ropinirole (because of
insomnia). He resumed playing the “World of Warfare” and
reported greater disinhibited sexuality and renewed
hyperfocusing. A long treatment hiatus ensued. Thirty-six
months into treatment, the patient’s dextroampheta-
mine/amphetamine and anti-depressant (duloxetine) had
again to be tapered, because of insurance reasons. At this
time the relevance of reward deficiency syndrome was again
discussed, along with the potential use of KB220Z-nutri-
genomic amino-acid therapy (NAAT), a natural D2 agonist,
and other nutraceuticals like L-tryptophan as substitutes for
his prescription medications. The patient’s ongoing insur-
ance denials, need for prior approvals, being in and out of
the “doughnut hole” made this seem like a worthwhile solu-
tion. The patient was, unfortunately, could not afford to pur-
chase these products and one of us (TM) did not at that time
have access to samples. Dextroamphetamine/amphetamine
was later re-introduced along with ropinirole, when insur-
ance difficulties had been resolved.
Thirty-eight months into treatment, his dextroampheta-
mine/amphetamine and duloxetine were regularly added and
decreased, primarily for insurance and financial reasons.
When maintained on both medications, he was relatively
more able to focus and be euthymic. Forty months into treat-
ment, he was abusing benzodiazepine and had not taken
dextroamphetamine/amphetamine for three weeks. Dextro-
amphetamine/amphetamine was again re-initiated. Along
hiatus in treatment ensued.
Fifty-three months into treatment, dextroampheta-
mine/amphetamine was discontinued and lisdexamfetamine
60 mg was prescribed for 10 days, with an increase to 70 mg.
Fifty months into treatment, the patient reported he was
stable and felt “more mellow” on the lisdexamfetamine. He
also noted, increased motivation as well as decreased pro-
crastination and social anxiety. Following this, lisdexam-
fetamine was denied by his insurance company and his med-
ications again changed to dextroamphetamine/amphetamine
and duloxetine, the latter in the form of samples.
Fifty-seven to sixty months into treatment, the patient
had been off stimulants for three months. He reported de-
creased motivation. For insurance and regional shortages
reasons, methylphenidate 10 mg was started, along with
L-tyrosine 500 mg for one week and, then 1000 mg. The ra-
tionale was derived from the literature on reward deficiency
syndrome. Methylphenidate was increased to 10 mg twice a
day and L-tyrosine increased to 1500 mg. He continued on
duloxetine samples at 60 mg bid. In the sixtieth month of
treatment, he reported a chronic tendency to pull his hair,
both pubic and otherwise as well as pull on scabs. In the
sixty-second month of treatment, the patient overdosed on
his girlfriend’s meds in combination with alcohol. He also
threatened to cut his wrists, because she was breaking up
with him. The patient was involuntarily hospitalized. In the
sixty-fourth month of treatment, the patient reported a de-
crease from daily pornography watching to weekly watch-
ing. Methylphenidate, which had to be again substituted for
dextroamphetamine/amphetamine was 10 mg a day. His
methylphenidate was increased to 10 mg twice a day. In the
sixty-fifth month of treatment, he reported decreased sexual
impulsivity. His methylphenidate was discontinued due to
side effects. Dexedrine had been initiated and increased
from 10 mg a day, eventually in 10 mg doses to 20 mg bid.
In the sixty-sixth month of the treatment, the patient
stated that, as a child of between 8–9 years of age, he would
defecate behind the sofa in the living room. He and his fam-
ily would blame the dog. This was explained as another
manifestation of his limbic disinhibition (Comings, 1994).
In the seventieth month of treatment, the patient stated that
he was increasingly sexually disinhibited and he complained
of an increase in his pornography addiction. Methylpheni-
date was increased to 10 mg three times a day. The regional
shortage of all stimulants worsened.
History of sexually disinhibited behavior,
history according to patient’s girlfriend
GF had been dating her boyfriend at the time for six years,
prior to his psychiatric intake evaluation by TM. Eighteen
months into their treatment, GF states the patient was engag-
ing “sadistic tickling near her vagina”. Twenty-four months
into their treatment, patient complained of the patient in-
creased sexual impulsivity and blatant and provocative exhi-
bitionism in their apartment. He would also express sexual
interest in the GF’s younger niece. Twenty-five months into
treatment, the patient was sexually disinhibited, impulsive
and exhibiting vocal and motor tics. Forty months into treat-
ment, GF broke up with the patient, because of his
“hypersexuality” and because he was off his medications
due to ongoing, insurance problems. Forty-two months into
treatment, GF complained of the aggressive and impulsive
nature of the patient’s sexual approach to her. Fifty months
into treatment, GF complained of a sexual assault by the pa-
tient. Fifty-one months into treatment, GF complained of
boyfriend’s sexually disinhibited behavior and her willing-
ness to call the police. The patient continued to be sexually
inappropriate on another occasion that month. The patient
also threatened suicide, because GF refused to continue their
romantic relationship. Fifty-two months into treatment pa-
tient was again sexually disinhibited and exhibitionistic.
A lengthy treatment hiatus ensued. Seventy-two months
into treatment, patient complained about the ex-boyfriend
entering into her room despite her protestations. Eighty-two
months into treatment, GF complained that her boyfriend
was “hypersexual”.
Rapid clinical response to KB220Z-NAAT
Then TM provided free KB220Z-NAAT. GF agreed to en-
sure that tablets were taken on an empty stomach by the pa-
tient. One week later, GF reported that the patient was taking
KB220Z-NAAT faithfully. After one week, GF noted that
the patient 1) was able to shovel her car out from the
snow/blizzard (a rare event); 2) went shopping with her (a
rare event); 3) had cleaned the cat litter box (a rare event); 4)
took the trash out (a rare event); 5) was checking for travel
websites to visit places they had planned to go to together a
number of years prior; 6) did not engage in his frequent habit
of hugging her against her wishes, exposing himself to her,
taunting about sex, etc. In addition, he no longer attempted
to hug against her will but would instead, occasionally ca-
ress her cheek with his hand.
Protracted positive response to KB220Z
The patient stated that he took the KB220Z, two pills twice a
day faithfully for three weeks. He followed the instructions,
always taking the pills on an empty stomach. Nevertheless,
for unclear and, possibly, motivational reasons, he stopped
taking them for the fourth week, despite their salutary effects
(Fig. 1).
His current, live-in, former girlfriend was present for the
most recent interview. She confirmed the patient’s behavior
was consistent with his subjective report about the effects of
KB220Z on his mental, motivational and libidinal func-
tioning.
As an example of his perceived effect of KB220Z, the
patient reported a marked improvement in concentration for
the entire three-week period, rating his new ability at 90%,
out of a maximum 100%.
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Figure 1. Illustrates positive benefits in a medication refractive Tourette’s patient with paraphilias during a three-week treatment
with KB220Z
In addition, he stated his procrastination tendency, which
had been a severe motivational problem, was reduced to
30% out of a maximum 100%. He noted that boredom was
significantly reduced for the three weeks to 10% of maxi-
mum 100%.
He reported that his sexual impulsivity was significantly
reduced from 100% to 40% for three weeks on KB220Z.
This estimate was emphatically confirmed by his female
friend, who had had to endure his disinhibition for many
months.
The patient also noted that his addiction to pornography
was more under control and had decreased to only once a
day from a much greater need. He added that he had a de-
creased need to “taunt” (tease) former girlfriend, which ef-
fect lasted for the entire month, i.e., even after he stopping
the KB220Z.
His female friend stated that, on KB220Z, his sexual
aggressiveness and disinhibition, which they both rated as
100% = maximum, was reduced to 40%, with respect to his
pestering her, verbally and behaviorally. For the third week
of the month, when he was no longer taking the KB220Z, his
sexual aggressiveness returned to 85% of his maximal, base-
line state.
Interestingly, the patient added, for the three weeks he
took the KB220Z: “I was taking things from the back of my
mind to the front of my mind”. By this he meant, he was able
to put himself in the position of, for example, the couple’s
cat (who had to endure a dirty litter box) and that he could
also put himself in the position his female friend and attend
more to her needs. In addition and remarkably, even though
he stopped taking the KB220Z for the last week of his
month’s supply, the patient reported: “I am still able to think
in terms of others, such as, cleaning the cat litter box and do
the dishes for my (former) girlfriend”.
To summarize, the patient stated that for the week when
he stopped his KB220Z, his sexual impulsiveness had now
returned to 85% of maximum (confirmed by female friend).
His concentration was now reduced to 5% of 100% maxi-
mum and procrastination was 80% maximum debilitating
effect. Boredom did not constitute a significant problem.
Questions raised by this patient’s response to KB220Z
center around his, possibly, new-found ability to think altru-
istically i.e., from the point of view of the other, namely, in
this case, his cat and his female friend. Even more remark-
able is his report that this new-found attitude was persisting,
even though he had stopped taking KB220Z for one week.
An important consideration, of course, concerns the
half-life of KB220Z, which other than rhodiola, especially
the amino-acid precursors have a short 4-hour half-life. We
do not expect that this attitude change is due to pharmaco-
logically mediating his new psychological perspective. On
the other hand, if it is 5 1/2 half-lives have dissipated in one
week, it is possible that the patient was able to learn new be-
haviors and attitudes and begin to think more altruistically,
in terms of the needs and perspective of others. It is possible
that such newly learned behaviors might continue into the
future.
In addition, even though off the KB220Z, he was still
able to vacuum a donated but dirty car. Finally, the patient
was able to come to his medical appointment for the first
time in five weeks and did not evidence any lack of enthusi-
asm or lack of motivation as he related to the physician.
(Prior to taking KB220Z, even though he was taking maxi-
mal dextroamphetamine/amphetamine, attending his ap-
pointment was inconsistent. The effects described above oc-
curred without any additional dopamine agonist, pharmaco-
logical agent.)
While this is a profound clinical response it is short lived
and requires more in-depth study especially in a large cohort
against placebo control.
DISCUSSION
A recent article from the Cross-Disorder Group of the Psy-
chiatric Genomics Consortium (2013), suggest that genetic
contributions to psychiatric disorders do not in all cases map
to present diagnostic categories. The authors aimed to iden-
tify specific variants underlying genetic effects shared be-
tween the five disorders in the Psychiatric Genomics Con-
sortium: autism spectrum disorder, attention deficit-hyper-
activity disorder, bipolar disorder, major depressive disor-
der, and schizophrenia. They analyzed genome-wide sin-
gle-nucleotide polymorphism (SNP) data for the five disor-
ders in 33,332 cases and 27,888 controls of European ances-
try. SNPs at four loci surpassed the cutoff for genome-wide
significance (p < 5 × 10–8) in the primary analysis: regions
on chromosomes 3p21 and 10q24, and SNPs within two
L-type voltage-gated calcium channel subunits, CACNA1C
and CACNB2. Polygenic risk scores showed cross-disorder
associations, notably between adult-onset disorders. Path-
way analysis supported a role for calcium channel signaling
genes for all five disorders. Their findings suggest that spe-
cific SNPs are associated with a range of psychiatric disor-
ders of childhood onset or adult onset. In particular, varia-
tion in calcium-channel activity genes seems to have
pleiotropic effects on psychopathology. These results pro-
vide evidence relevant to the goal of moving beyond de-
scriptive syndromes in psychiatry, and towards a nosology
informed by disease cause (Cross-Disorder Group of the
Psychiatric Genomics Consortium et al., 2013).
We point out this new finding because the suggestion of
a common genetic antecedent as proposed by Blum et al.
(1990, 1996) over 18 years ago on reward deficiency syn-
drome seems pivotal to the mechanisms involved in psychi-
atric disorders uniting potential therapeutic targets. Our lab-
oratory continuously highlights the importance of providing
dopaminergic agonist therapy for all behavioral addictions.
The primary clinical issue in terms of dopaminergic agonist
therapy has been the utilization of powerful agonists such as
pharmaceuticals such as ropinirole, whereby long term use
may result in down regulation D2 receptors (Blum, Gardner,
Oscar-Berman & Gold, 2012). We on the other hand do not
support the concept of reducing dopaminergic activation in
the long term (Blum et al., 2008), which has now been sug-
gested by utilizing for example, Calcium channel blockers
(Cross-Disorder Group of the Psychiatric Genomics Con-
sortium et al., 2013). We refer to the development of
rimonabant (Li & Cheung, 2011) which blocks dopamine
release via GABAergic stimulation, which induces suicide
ideation and as such rejected by the US FDA (Derosa &
Maffioli, 2012).
It is noteworthy that ropinirole acts as a D2, D3, and D4
dopamine receptor agonist with highest affinity for D2. It is
weakly active at the 5-HT2, and a2 receptors and virtually no
affinity for many other neurotransmitter receptors (Eden et
al., 1991). Long-term exposure to quinpirole, pramipexole
and ropinirole (which possess negligible affinities for D (1)
122 | Journal of Behavioral Addictions 2(2), pp. 117–124 (2013)
McLaughlin et al.
sites) elicited supersensitivity of adenyl cycles by interact-
ing at D1/D2/D3 receptors. Interpretation of these result sug-
gests that ropinirole following chronic use may induce down
regulation of D2 receptors and central tolerance to its effects
(Aloisi, Silvano, Rossi, Millan & Maggio, 2011). We have
suggested earlier that supersensitivity will induce relapse of
addictive behaviors (Blum et al., 2009).
Given the long history of refractive response to
psychotropic medication and the potential of overall RDS
behaviors including drug abuse as well, one of us (TM)
thought that a natural less powerful D2 agonist such as
KB220Z might provide some rapid relief of “hyper-
sexuality” and repetitive paraphilia behavior. Based on a
number of recent neuroimaging articles published (Blum
et al., 2010; Miller et al., 2010) concerning the rapid onset of
dopaminergic activation occurring one hour post adminis-
tration, it is not surprising to obtain rapid relief of AC’s
paraphilias. However, while the outcome looks promising it
could be short lived and must await larger long-term placebo
controlled studies before any real interpretation could be
garnished. We are encouraged because many previous clini-
cal trials on KB220Z-NAAT and variants have shown long-
term effects without dangerous side effects such as suicide
ideation with links to reward circuitry improvements (Blum,
Giordano et al., 2012; Blum & Gold, 2011; Blum, Liu,
Shriner & Gold, 2011; Blum, Oscar-Berman et al., 2012).
CONCLUSIONS
Based on previous scientific evidence showing KB220Z-
nutrigenomic amino-acid therapy (NAAT) to rapidly (post
one-hour) activate dopaminergic pathways in both the
pre-frontal cortex cingulate gyrus (relapse loci) and ventral
tegmental area–caudate–accumbens–putamen (craving and
emotion loci) the patient was prescribed KB220Z-NAAT.
Within one week of utilization the repetitive paraphilia was
eliminated. While this report focused on a rapid response
rather than long-term benefits previously associated with
NAAT, it is somewhat encouraging and longer term re-
quired follow-up and larger placebo controlled studies are
warranted before any definitive conclusions could be
gleaned from this case report.
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